US filing for Avastin in first-line ovarian cancer 'unlikely' despite European nod
This article was originally published in Scrip
The European Commission has approved Avastin (bevacizumab) from Roche in combination with chemotherapy for front-line advanced ovarian cancer, but Roche says that there is a "low likelihood" of a US filing in the first-line setting.
You may also be interested in...
Genentech says it worked closely with the agency to bring the drug to women with earlier-stage disease.
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.